


# Oncology Molecular Diagnostics Market Set to Hit \$6.46B by 2033 Amid AI & Liquid Biopsy Surge

Global oncology molecular diagnostics market grows rapidly, driven by Al, NGS, liquid biopsy, and expanding personalized oncology adoption.

LOS ANGELES, CA, UNITED STATES, October 24, 2025 /EINPresswire.com/ -- The Oncology Molecular Diagnostics Market reached US\$ 3.59 billion in 2023, grew to US\$ 3.79 billion in 2024, and is projected to reach US\$ 6.46 billion by 2033, registering a CAGR of 6.2% during the forecast period 2025–2033.



Top Key Players: Abbott, QIAGEN, F. Hoffmann-La Roche Ltd, BD, Cepheid, Hologic, Inc., Sysmex Corporation, Bio-Rad Laboratories, Inc., Foundation Medicine, Inc., and ASURAGEN, INC.



Molecular diagnostics are revolutionizing cancer care, enabling early detection, precise monitoring, and personalized therapies."

DataM Intelligence

United States – Industry News
☐ OncoHost expands availability of PROphetNSCLC® test
On October 22, 2025, OncoHost received a New York State

laboratory permit, enabling broader access to its PROphetNSCLC® precision oncology test.

☐ BillionToOne files for U.S. IPO

On October 7, 2025, molecular diagnostics firm BillionToOne filed for an initial public offering on the Nasdaq, aiming to capitalize on renewed investor interest.

☐ Hologic to go private in \$18.3 billion deal

On October 21, 2025, Hologic announced plans to be acquired by Blackstone and TPG in a deal

valued at up to \$18.3 billion, focusing on women's health diagnostics.

### Japan – Industry News

☐ Sysmex partners with QIAGEN for exclusive distribution

On October 1, 2025, Sysmex and QIAGEN concluded an exclusive agreement to distribute QIAGEN's clinical diagnostic instruments and reagents in Japan.

☐ A.D.A.M. Innovations and SOPHiA GENETICS partner for liquid biopsy

On October 16, 2025, A.D.A.M. Innovations and SOPHiA GENETICS announced a partnership to advance liquid biopsy testing and companion diagnostics in Japan.

☐ Illumina's TruSight Oncology Comprehensive receives regulatory approval

On May 26, 2025, Illumina's TruSight™ Oncology Comprehensive test for cancer genomic profiling received regulatory approval in Japan.

South Korea – Industry News

☐ Seegene launches STAgora platform

In July 2025, Seegene launched STAgora, a real-time infectious disease analytics platform integrating diagnostic data with AI and statistical modeling.

### Europe - Industry News

☐ Roche acquires 89bio for metabolic disease treatment

On October 23, 2025, Roche announced a merger agreement to acquire 89bio and its phase III FGF21 analogue for the treatment of metabolic dysfunction-associated steatohepatitis.

☐ AstraZeneca to acquire EsoBiotec for up to \$1 billion

On March 17, 2025, AstraZeneca announced an agreement to acquire biotechnology company EsoBiotec for up to \$1 billion, aiming to bolster its cell therapy capabilities.

☐ Broad Institute and Illumina launch Al-integrated precision medicine research platforms In April 2025, the Broad Institute and Illumina launched Al-integrated precision medicine research platforms combining genomics, transcriptomics, and biomarker analytics.

Looking For A Detailed Full Report? Get it here: <a href="https://www.datamintelligence.com/buy-now-page?report=oncology-molecular-diagnostics-market">https://www.datamintelligence.com/buy-now-page?report=oncology-molecular-diagnostics-market</a>

# **Market Segmentation**

- By Product Type (Reagents, Instruments, and Software)
- By Technology (Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), In Situ Hybridization (ISH), and Others)
- By Application (Breast Cancer, Prostate Cancer, Colorectal Cancer, Cervical Cancer, Liver Cancer, Lung Cancer, Blood Cancer, and others)
- By End-User (Hospitals, Clinical Laboratories, and Others)

# Regional Insights

• North America: Dominated the market in 2024 with a share of 44.69%, attributed to strong healthcare infrastructure, high cancer incidence, and robust adoption of molecular diagnostic

## technologies.

- Asia-Pacific: Expected to witness the fastest growth during the forecast period, driven by increasing cancer awareness, improving healthcare access, and government initiatives in countries like China and India.
- Europe: Experiencing steady growth, supported by national screening programs and a shift towards personalized oncology care.

### **Key Market Segments**

- ☐ By Cancer Type:
- o Breast Cancer: Held the largest market share in 2024, driven by early detection programs and targeted therapies.
- o Liver Cancer: Anticipated to grow at a remarkable CAGR of 13.9% between 2025 and 2034.
- ☐ By Technology:
- o PCR: Led the market with over 32% share in 2024.
- o NGS: Expected to expand at the fastest CAGR, offering comprehensive genomic profiling capabilities.
- ☐ By Sample Type:
- o Tissue Biopsy: Retained a significant share in 2024.
- o Liquid Biopsy: Advancing rapidly with a CAGR of 14.32%, enabling non-invasive cancer detection.
- ☐ By Product:
- o Reagents: Dominated the market with over 59% share in 2024

# Get Customization in the report as per your requirements:

https://www.datamintelligence.com/customize/oncology-molecular-diagnostics-market

### **Future Outlook**

The oncology molecular diagnostics market is poised for significant growth, driven by:

- Technological Innovations: Advancements in Al-driven diagnostics and the development of more efficient molecular profiling tools.
- Integration into Clinical Practice: Increased incorporation of molecular diagnostics into routine clinical workflows for cancer detection and monitoring.
- Global Expansion: Efforts to improve healthcare access and infrastructure in emerging markets, facilitating broader adoption of molecular diagnostic technologies.

### Related Reports:

Molecular Diagnostics Market 2025
POC Molecular Diagnostics Market

Kailas Disale DataM Intelligence 4market Research LLP +1 877-441-4866 email us here This press release can be viewed online at: https://www.einpresswire.com/article/861169112

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.